• PDF / 176,289 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 32 Downloads / 149 Views

DOWNLOAD

REPORT

---

S

Various toxicities: 4 case reports In a study, four women aged 32–50 years were described, who developed various toxicities during treatment with sunitinib or docetaxel for metastatic breast cancer [routes not stated; not all durations of treatments to reactions onset and outcomes stated]. Case 1: A 50-year-old woman, who was diagnosed with grade 3 metastatic multifocal ductal breast carcinoma, started receiving treatment with sunitinib 37.5mg daily for 2 weeks followed by 1 week off treatment (Schedule 2/1) along with docetaxel 75 mg/m2 on day 1 every 3 weeks, for 20 cycles. Additionally, she was receiving treatment with various concomitant medications. She developed pain in the tongue and swelling of the neck and face associated with sunitinib. Swelling developed on the 17th day of sunitinib treatment and was reduced following initiation of pre-treatment with steroids. She developed diarrhoea and fatigue associated with sunitinib and docetaxel. Also, she had hoarseness secondary to common cold [aetiology not stated]. During cycles 15–20, the dose of docetaxel was reduced to 60 mg/m2 due to fatigue associated with docetaxel. Subsequently, her fatigue recovered. After treatment with sunitinib and docetaxel, stable disease was maintained for 13 months with good QoL (Karnofsky score). However, after 20 cycles disease progression was noted. Case 2: A 49-year-old woman, who was diagnosed with grade 3 metastatic invasive ductal breast carcinoma, started receiving treatment with sunitinib 37.5mg daily for 2 weeks followed by 1 week off treatment (Schedule 2/1) along with docetaxel 75 mg/m2 on day 1 every 3 weeks, for 12 cycles. Additionally, she was receiving treatment with various medications and radiotherapy concomitantly. After the treatment 50% decrease in liver metastases was noted. She developed grade 1 sensory neuropathy associated with docetaxel. On the ninth day of cycle 2, the treatment with docetaxel was discontinued due to grade 4 neutropenia and grade 1 fever associated with docetaxel. She was hospitalised for 4 days due to neutropenia and fever, which was treated with unspecified antibiotics. Her treatment was restarted at reduced doses of sunitinib 25mg daily, for cycles 3–12 and docetaxel 60 mg/m2, for 2 weeks followed by 1 week off treatment (Schedule 2/1) for cycles 3–10. Additionally, she developed grade 1 adverse events including heartburn, diarrhoea, fatigue, myalgia, rash and arthralgia associated with sunitinib and docetaxel. Her QoL (Karnofsky score) was good with ability to maintain daily living activities. However, after 12 cycles disease progression was noted. Case 3: A 32-year-old woman, who was diagnosed with grade 3 metastatic invasive ductal breast carcinoma, started receiving treatment with sunitinib 37.5mg daily for 2 weeks followed by 1 week off treatment (Schedule 2/1) along with docetaxel 75 mg/m2 on day 1 every 3 weeks, for 6 cycles. After only two cycles of treatment stable disease (SD) was noted. Due to excellent tolerability, the dose of sunitinib was increased to 50mg daily in